about
Identification of an antimalarial synthetic trioxolane drug development candidateComputational prediction of formulation strategies for beyond-rule-of-5 compoundsStructure-Guided Lead Optimization of Triazolopyrimidine-Ring Substituents Identifies Potent Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors with Clinical Candidate PotentialMalarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised targetSelf-micellization of gemfibrozil 1-O-beta acyl glucuronide in aqueous solution.Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrine.The interaction of lipophilic drugs with intestinal fatty acid-binding protein.A mouse model to evaluate the impact of species, sex, and lipid load on lymphatic drug transportExamination of oral absorption and lymphatic transport of halofantrine in a triple-cannulated canine model after administration in self-microemulsifying drug delivery systems (SMEDDS) containing structured triglycerides.Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation.Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria.The structure-activity relationship of the antimalarial ozonide arterolane (OZ277).Murine GPRC6A Mediates Cellular Responses to L-Amino Acids, but Not Osteocalcin VariantsComputational prediction of drug solubility in lipid based formulation excipients.Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice50years of oral lipid-based formulations: Provenance, progress and future perspectives.Synthesis, structure-activity relationships and brain uptake of a novel series of benzopyran inhibitors of insulin-regulated aminopeptidase.Isoform-Specific Biased Agonism of Histamine H3 Receptor Agonists.Antimalarial activity of pyrroloiminoquinones from the Australian marine sponge Zyzzya sp.Label-Free Kinetics: Exploiting Functional Hemi-Equilibrium to Derive Rate Constants for Muscarinic Receptor Antagonists.Trypanothione reductase high-throughput screening campaign identifies novel classes of inhibitors with antiparasitic activity.Stability of peroxide antimalarials in the presence of human hemoglobin.An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine.Targeted drug delivery to lymphocytes: a route to site-specific immunomodulation?Characterisation and quantification of medium chain and long chain triglycerides and their in vitro digestion products, by HPTLC coupled with in situ densitometric analysis.A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine.The impact of P-glycoprotein efflux on enterocyte residence time and enterocyte-based metabolism of verapamil.Separation and characterization of the colloidal phases produced on digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly water-soluble drugs.Does stereoselective lymphatic absorption contribute to the enantioselective pharmacokinetics of halofantrine In Vivo?Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs.Partitioning of halofantrine hydrochloride between water, micellar solutions, and soybean oil: Effects on its apparent ionization constant.Intravenous dosing conditions may affect systemic clearance for highly lipophilic drugs: implications for lymphatic transport and absolute bioavailability studies.Probing drug solubilization patterns in the gastrointestinal tract after administration of lipid-based delivery systems: a phase diagram approach.Evaluation of the impact of altered lipoprotein binding conditions on halofantrine induced QTc interval prolongation in an anaesthetized rabbit model.Influence of physicochemical properties on the patterns of association of a series of aliphatic esters of halofantrine with plasma lipoproteins.Orally active antimalarials: hydrolytically stable derivatives of 10-trifluoromethyl anhydrodihydroartemisinin.Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations.Drug solubilization behavior during in vitro digestion of suspension formulations of poorly water-soluble drugs in triglyceride lipids.A novel cubic phase of medium chain lipid origin for the delivery of poorly water soluble drugs.Degradation of berenil (diminazene aceturate) in acidic aqueous solution.
P50
Q22061876-57D55940-5654-4CB9-83D0-DFE8872AFDC1Q26765392-7767F43F-2814-4369-A46B-3E91C4C0A70BQ27670499-CF616A97-1D6C-4192-9FD3-F3BF109731E7Q27674154-9588F51D-CE34-48B1-A477-2EECE7BA7080Q30782694-911A3A7D-4EA7-4A60-A8E9-C0375652D57EQ30919545-CD229A6F-E2AB-4592-ABA5-E494F02CF43EQ30983194-B635CE4A-DC59-4F5B-B87E-AB5DE8167EFDQ34060125-547C854E-1F89-417E-81AD-AE869C864557Q34246873-0569A08E-9A45-4AEA-BF0C-6A3FDA32CE13Q34347433-7541A3DD-5621-44EB-BAD7-7965605DC539Q34693880-2E4288A8-D39D-4000-AA08-1533C1B002DEQ35013670-CC2C2D61-8765-4C01-8767-D99C77AD0D1BQ35897933-F271FDCF-7C25-4841-8F95-16AF5A8DF2EDQ37345633-A8E50710-3206-426C-B05D-AC79C79525BCQ37352712-9C638F4E-950F-41F7-A1BF-3AE0413FF22AQ38811050-9209F383-FAA9-4CD0-9035-5451DE5E3728Q39029717-1ED995A4-2390-4F86-9019-063F2EFFD81FQ39173097-8E860208-57B7-4B1C-B335-A7D7AB0A90AAQ39333451-FA06621E-64B5-4033-BB8F-99613AD541A5Q40659394-5CC582F6-46F3-47E6-A42F-908C37F6E29EQ41824183-1E73F9A7-E732-485E-973E-19AEC17EC800Q41912806-327E63C9-F939-4F4B-B3DB-955E708DF997Q42050629-E2B3F36C-5ECB-4C15-9B46-62148BE5DF61Q42854469-A6678F53-D017-4615-8EBF-57000171513FQ43620194-7DE4764F-8588-4234-8C90-7E9B54458F4DQ43824724-F15D286F-AE6E-428B-8980-FDF7713895FFQ43862251-15481DDC-E86E-407A-8BE2-711BEEF9AA56Q44315619-A4B9777D-C58F-49C6-9E60-9202F6A98BFDQ44405724-E0045801-151B-41C9-BEAA-30C80D7B9B5FQ44478904-38545140-0349-4A0F-80EE-9B6D5D0EA458Q44645966-4118CE11-D776-48CE-A368-8024163193E4Q44659890-F326A4DA-6D4A-4675-9F07-9164A0FD9EE8Q44713260-B0971624-57C3-4B4A-9F55-0B05C0E49B69Q44773929-C59D0387-A65A-47BB-827E-4203231DBD61Q44774564-4B44931A-D56B-472E-BFAC-156AE41B1EFFQ44784868-2B30CE3A-87AE-4CD2-B31C-B0487096EE47Q44806110-593AF83A-A5CD-4F7B-92F6-85819CC28432Q44806112-F5A44DF1-D9B9-4C66-B849-6DC06694425AQ45068539-AE494C1E-B948-4C73-8D89-1B0392252B0BQ45105477-05814910-4B57-4D36-82D3-7436732E3D3A
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
William N. Charman
@ast
William N. Charman
@en
William N. Charman
@es
William N. Charman
@nl
William N. Charman
@sl
type
label
William N. Charman
@ast
William N. Charman
@en
William N. Charman
@es
William N. Charman
@nl
William N. Charman
@sl
altLabel
Bill Charman
@en
prefLabel
William N. Charman
@ast
William N. Charman
@en
William N. Charman
@es
William N. Charman
@nl
William N. Charman
@sl
P1006
P214
P244
P1006
P106
P1153
24439189700
P21
P213
0000 0001 1595 3873
P214
P244
P31
P496
0000-0002-7051-2023
P7859
lccn-n91800429